Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
June 2016
-
Media ReleaseNovartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatmentNovartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
-
Media ReleaseNovartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten GenerationNovartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…
-
Media ReleaseNovartis étend son partenariat avec Medicines for Malaria Venture pour développer la prochaine génération de traitement antipaludéenNovartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &…
-
Media ReleaseNovartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorderEXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
-
Media ReleaseNovartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data…
-
In The NewsNovartis Access perspectives: Expanding access to healthcare: What will it really take?A Medium post by Steve Davis, CEO of PATH
-
Cancer researchers ready to aim for cures
New head of oncology research hopes to build on recent advances, explore new therapeutic approaches and beat certain cancers for good.
-
Confidence led this researcher to swim against the current
A researcher reflects on her successful journey from Venezuela to the US in which she became a doctor, a scientist, and a mother.
-
Media ReleaseNew data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator productsSandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] …
-
Media ReleaseNovartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine preventionPhase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability,…
-
The future of chronic myeloid leukemia is evolving
-
Media ReleaseNovartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …
Pagination
- ‹ Previous page
- 1
- …
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- …
- 152
- › Next page